<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006106</url>
  </required_header>
  <id_info>
    <org_study_id>DFCI-98320</org_study_id>
    <secondary_id>CDR0000068117</secondary_id>
    <secondary_id>NCI-G00-1832</secondary_id>
    <nct_id>NCT00006106</nct_id>
  </id_info>
  <brief_title>ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase I Study of Intraarterial ONYX-015 in Combination With Intravenous Cisplatin and Fluorouracil in Patients With Advanced Squamous Cell Cancer of the Head and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: A specially modified virus called ONYX-015 may be able to kill tumor cells while&#xD;
      leaving normal cells undamaged. Drugs used in chemotherapy use different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. Combining ONYX-015 with chemotherapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of ONYX-015 combined with cisplatin and&#xD;
      fluorouracil in treating patients who have advanced head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the feasibility and maximum tolerated dose (MTD) of intraarterial ONYX-015 in&#xD;
      patients with advanced squamous cell cancer of the head and neck.&#xD;
&#xD;
      II. Determine the feasibility and tolerability of intraarterial ONYX-015 at the MTD OR&#xD;
      maximum theraputic dose, whichever is lower, in combination with intravenous cisplatin and&#xD;
      fluorouracil in these patients.&#xD;
&#xD;
      III. Determine the qualitative distribution of ONYX-015 within a limited tumor biopsy and a&#xD;
      normal mucosal biopsy at different dose levels.&#xD;
&#xD;
      IV. Determine the response of these patients to intraarterial ONYX-015. V. Determine the&#xD;
      response of these patients to cisplatin and fluorouracil following intraarterial ONYX-015.&#xD;
&#xD;
      PROTOCOL OUTLINE: This is a dose escalation study. Patients receive intraarterial infusions&#xD;
      of ONYX-015. Treatment repeats once in 3-4 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-8 patients receive escalating doses of ONYX-015 until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 patients&#xD;
      experience dose limiting toxicity.&#xD;
&#xD;
      Patients in cohorts 1-4 are followed for 5 days after infusion, weekly for 3 weeks, at week&#xD;
      6, and monthly thereafter for 4 months.&#xD;
&#xD;
      A fifth or final cohort of 10 patients will receive ONYX-015 at the MTD. If the MTD was not&#xD;
      determined in cohorts 1-4, patients receive the highest dose administered to cohort 4.&#xD;
      Beginning 1-2 days after ONYX-015 infusion, patients receive cisplatin IV over 30-60 minutes&#xD;
      once and fluorouracil IV continuously over 4 days. Treatment repeats in 4 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity. Cisplatin and fluorouracil IV&#xD;
      treatment continues every 3-4 weeks at the discretion of the treating oncologist.&#xD;
&#xD;
      Patients in cohort 5 are followed for 5 days after initial infusion, weekly for 4 weeks, at&#xD;
      week 8, and monthly thereafter for 4 months.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A total of 23-28 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 1999</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Lip and Oral Cavity Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Oropharyngeal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONYX-015</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the head and neck (SCCHN) that is&#xD;
             incurable by standard therapy&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Multiple SCCHN primaries allowed&#xD;
&#xD;
          -  Metastases allowed if tumor to be treated is confined to head and neck region&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  Biologic therapy: Recovered from prior biologic therapy&#xD;
&#xD;
          -  Chemotherapy: At least 3 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  Endocrine therapy: Recovered from prior endocrine therapy&#xD;
&#xD;
          -  Radiotherapy: At least 12 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Surgery: Recovered from prior surgery&#xD;
&#xD;
          -  Other: Recovered from any prior diagnostic or theraputic procedures&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
          -  Age: 18 to physiologic 79&#xD;
&#xD;
          -  Performance status: ECOG 0-2&#xD;
&#xD;
          -  Life expectancy: Over 3 months&#xD;
&#xD;
          -  Hematopoietic: WBC greater than 3,000/mm3 OR Absolute neutrophil count greater than&#xD;
             2,000/mm3; Platelet count greater than 100,000/mm3; Hemoglobin greater than 10 g/dL&#xD;
             (transfusions allowed if not used solely to meet eligibility criteria)&#xD;
&#xD;
          -  Hepatic: SGOT less than 2.5 times upper limit of normal (ULN); Alkaline phosphatase&#xD;
             less than 3 times ULN; Bilirubin no greater than 1.5 times ULN&#xD;
&#xD;
          -  Renal: Creatinine less than 1.6 mg/dL OR Creatinine clearance greater than 50 mL/min&#xD;
&#xD;
          -  Cardiovascular: No active cardiovascular disease that would limit physical activity&#xD;
             (i.e., ability to walk 50 feet without stopping)&#xD;
&#xD;
          -  Pulmonary: No active pulmonary disease that would limit physical activity (i.e.,&#xD;
             ability to walk 50 feet without stopping)&#xD;
&#xD;
          -  Other: No other prior or concurrent malignancy within the past 3 years except limited&#xD;
             basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;&#xD;
             Adequate and nutritionally balanced enteral intake of at least 1,800 kcal/day (enteral&#xD;
             feeding tube dependent allowed); No intravenous alimentation as primary source of&#xD;
             calories; No other serious illness or medical condition that would preclude study&#xD;
             (i.e., active systemic lupus erythematosus, Crohn's disease or AIDS); No prior&#xD;
             immunodeficiency (i.e., HIV infection, organ transplant, or chronic steroid use); Not&#xD;
             pregnant or nursing; Negative pregnancy test; Fertile patients must use effective&#xD;
             contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall R. Posner</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>August 3, 2000</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>cellular diagnosis, hypopharyngeal cancer</keyword>
  <keyword>cellular diagnosis, laryngeal cancer</keyword>
  <keyword>cellular diagnosis, lip and oral cavity cancer</keyword>
  <keyword>cellular diagnosis, nasopharyngeal cancer</keyword>
  <keyword>cellular diagnosis, oropharyngeal cancer</keyword>
  <keyword>cellular diagnosis, paranasal sinus and nasal cavity cancer</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>hypopharyngeal squamous cell carcinoma</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>laryngeal squamous cell carcinoma</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>lip and oral cavity squamous cell carcinoma</keyword>
  <keyword>metastatic squamous neck cancer with occult primary</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>nasopharyngeal squamous cell carcinoma</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>oropharyngeal squamous cell carcinoma</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>paranasal sinus and nasal cavity squamous cell carcinoma</keyword>
  <keyword>recurrent hypopharyngeal cancer</keyword>
  <keyword>recurrent laryngeal cancer</keyword>
  <keyword>recurrent lip and oral cavity cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent nasopharyngeal cancer</keyword>
  <keyword>recurrent oropharyngeal cancer</keyword>
  <keyword>recurrent paranasal sinus and nasal cavity cancer</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage III hypopharyngeal cancer</keyword>
  <keyword>stage III laryngeal cancer</keyword>
  <keyword>stage III lip and oral cavity cancer</keyword>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage III oropharyngeal cancer</keyword>
  <keyword>stage III paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV hypopharyngeal cancer</keyword>
  <keyword>stage IV laryngeal cancer</keyword>
  <keyword>stage IV lip and oral cavity cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <keyword>stage IV oropharyngeal cancer</keyword>
  <keyword>stage IV paranasal sinus and nasal cavity cancer</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage, hypopharyngeal cancer</keyword>
  <keyword>stage, laryngeal cancer</keyword>
  <keyword>stage, lip and oral cavity cancer</keyword>
  <keyword>stage, metastatic squamous neck cancer with occult primary</keyword>
  <keyword>stage, nasopharyngeal cancer</keyword>
  <keyword>stage, oropharyngeal cancer</keyword>
  <keyword>stage, paranasal sinus and nasal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Lip Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Dl1520</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

